Evidence map›Paper›PMID 40030013›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2025

EGFR-induced lncRNA

Tanvi Saxena, Anan Quan, Erica Chan, Nina Kozlova, Latika Matai, Jonathan D Lee, Rajesha Rupaimoole, Francisco Beca, Taru Muranen, Frank J Slack

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. EGFR-induced lncRNAProceedings of the National Academy of Sciences of the United States of America · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Tanvi SaxenaHarvard Medical School Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Anan Quan *Harvard Medical School Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Erica Chan *Harvard Medical School Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.ORCID 0009-0007-6611-3904
Nina Kozlova *Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Latika MataiHarvard Medical School Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Jonathan D LeeHarvard Medical School Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Rajesha RupaimooleHarvard Medical School Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Francisco BecaHarvard Medical School Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.
Taru MuranenDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.ORCID 0000-0003-4158-9002
Frank J SlackHarvard Medical School Initiative for RNA Medicine, Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215.ORCID 0000-0001-8263-0409

Funding

Precision microRNA medicine in cancerR35CA232105 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI SLACK, FRANK J. · 2019 to 2025
$7.2M
HHS | NIH | National Cancer Institute (NCI) R35CA232105NCI NIH HHS R35 CA232105
6 · The paper itself

Abstract

Long noncoding RNAs (lncRNAs) play numerous roles in cellular biology and alterations in lncRNA expression profiles have been implicated in a variety of cancers. Here, we identify and characterize a lncRNA, TRIM28 Interacting DNA damage repair Enhancing Noncoding Transcript (

Indexed as

Carcinoma, Non-Small-Cell LungDNA RepairDrug Resistance, NeoplasmLung NeoplasmsRNA, Long NoncodingTripartite Motif-Containing Protein 28A549 CellsAnimalsCell Line, TumorCell ProliferationDNA DamageErbB ReceptorsGene Expression Regulation, NeoplasticHumansMicePhosphorylationEGFR protein, humanErbB ReceptorsRNA, Long NoncodingTRIM28 protein, humanTripartite Motif-Containing Protein 28DNA damage repairlncRNANSCLCTRIM28

Identifiers

PMID40030013
PMCPMC11912419

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.